Atria Wealth Solutions Inc. Purchases 665 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Atria Wealth Solutions Inc. raised its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 5.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 12,759 shares of the biotechnology company’s stock after buying an additional 665 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Sarepta Therapeutics were worth $1,230,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Sarepta Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock valued at $1,039,212,000 after buying an additional 41,465 shares during the period. Wellington Management Group LLP increased its holdings in Sarepta Therapeutics by 1.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,909,800 shares of the biotechnology company’s stock valued at $473,946,000 after buying an additional 54,698 shares during the period. Westfield Capital Management Co. LP increased its holdings in Sarepta Therapeutics by 40.1% in the 3rd quarter. Westfield Capital Management Co. LP now owns 806,400 shares of the biotechnology company’s stock valued at $97,752,000 after buying an additional 230,618 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Sarepta Therapeutics by 1.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 560,351 shares of the biotechnology company’s stock valued at $67,926,000 after buying an additional 6,309 shares during the period. Finally, Barclays PLC increased its holdings in Sarepta Therapeutics by 29.8% in the 3rd quarter. Barclays PLC now owns 517,286 shares of the biotechnology company’s stock valued at $62,705,000 after buying an additional 118,761 shares during the period. 86.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Evercore ISI raised their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a report on Tuesday, February 20th. TheStreet raised shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Mizuho lifted their price target on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Royal Bank of Canada lifted their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Finally, Wedbush reaffirmed an “outperform” rating and set a $224.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average price target of $156.60.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 1,200 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the transaction, the chief financial officer now owns 39,114 shares in the company, valued at approximately $5,018,326.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Ian Michael Estepan sold 1,200 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the transaction, the chief financial officer now owns 39,114 shares in the company, valued at approximately $5,018,326.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen Mayo sold 3,135 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total transaction of $385,479.60. Following the completion of the transaction, the director now owns 6,621 shares in the company, valued at approximately $814,118.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Trading Up 3.3 %

SRPT opened at $130.90 on Thursday. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.95 and a quick ratio of 3.45. The firm has a market capitalization of $12.37 billion, a price-to-earnings ratio of -21.39 and a beta of 0.94. The company’s 50 day moving average price is $125.80 and its two-hundred day moving average price is $110.42.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. During the same period in the previous year, the firm posted ($1.44) EPS. The company’s revenue for the quarter was up 63.1% compared to the same quarter last year. As a group, research analysts predict that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.